Jazz Pharmaceuticals (NASDAQ:JAZZ) Posts Earnings Results, Misses Expectations By $0.13 EPS

Jazz Pharmaceuticals (NASDAQ:JAZZ) posted its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $5.70 EPS for the quarter, missing analysts’ consensus estimates of $5.83 by ($0.13), Zacks reports. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. Jazz Pharmaceuticals updated its FY 2025 guidance to 22.500-24.000 EPS and its FY 2025 guidance to 22.500-24.000 EPS.

Jazz Pharmaceuticals Trading Up 2.2 %

Shares of NASDAQ:JAZZ traded up $2.98 during mid-day trading on Tuesday, reaching $139.67. 1,269,835 shares of the company were exchanged, compared to its average volume of 640,889. Jazz Pharmaceuticals has a 1 year low of $99.06 and a 1 year high of $140.52. The firm’s 50-day simple moving average is $125.08 and its 200 day simple moving average is $118.24. The firm has a market cap of $8.44 billion, a price-to-earnings ratio of 19.67, a P/E/G ratio of 1.04 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. This trade represents a 0.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 5,053 shares of company stock valued at $617,442 in the last three months. 4.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Robert W. Baird upped their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. TD Cowen dropped their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Finally, HC Wainwright restated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $180.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.